Annexon highlights leadership in advancing clinical research and education for guillain-barrÉ syndrome (gbs) at american academy of neurology (aan) 2025 annual meeting

Oral plenary presentation on tuesday, april 8 features phase 3 data for anx005, the first potential targeted therapy for gbs, showing rapid and durable benefit across clinical measures and time points

ANNX Ratings Summary

ANNX Quant Ranking